Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, and OBI-3424

Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer. Poster / Abstract number: TPS611 Title:First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors Poster / Abstract number: 3029 Title: Safety, Pharmacokinetics, and Clinical Activity of OBI-3424, an AKR1C3-Activated Prodrug, in Patients with Advanced or Metastatic Solid Tumors: A Phase 1 Dose-Escalation Study Poster / Abstract number: 3030

The release as fetched from its publisher. obipharma.com ↗